QVT Financial LP

QVT Financial LP sold 1,225,784 shares ($32.7M) at $26.64 avg; retains 15.13M shares post-transaction.

QVT Financial LP executed 5 separate sales totaling 1,225,784 shares for $32,658,518.16 between 2026-02-11 and 2026-02-13 at a blended average price of $26.64, reducing holdings by 7.5%. The company trades near its 52-week high (current price $26.45 vs 52-week high $27.67, -4.4%) following strong recent momentum (90-day return +30.4%). However, Roivant Sciences is unprofitable with net income of $-265,891,000.00 and revenue declining 76.7% year-over-year, with only $1,999,000.00 in latest quarterly revenue. QVT's prior open-market trading across all tickers shows a 0.00% well-timed rate on 17 prior sells, and recent same-ticker sales (December 2025) exhibit modest positive 30-day returns, providing no clear timing signal at this juncture.

QVT Financial LP sold 1,694,614 shares (1.69M) of ROIV for $39,065,213.44 ($39.1M) at avg $23.05, reducing holdings 9.4% across 5 transactions over 2 days.

QVT Financial LP executed 5 separate sales totaling 1,694,614 shares for $39,065,213.44 across December 16–17, 2025, at prices ranging from $22.93 to $23.17 (blended average $23.05), reducing stake from 18,047,727 to 16,353,113 shares (-9.4%). The timing is notable: the sales occurred near the 52-week high of $22.94, and stock is now trading at $21.79 (-5.0% from the high). Across his cross-ticker track record, the insider's 12 prior sells averaged a 90-day return of +0.6% with a 0.00% well-timed rate—indicating his prior sells have not preceded declines. However, at ROIV specifically, his single measurable prior sale (2024-09-26) saw the stock rise +1.5% in 90 days. Roivant is deeply unprofitable (net income $-113,519,000.00, annual revenue growth -76.7%), trades at a $15.2B market cap on minimal quarterly revenue ($1,571,000.00), and recent prior sales by this insider at this ticker (five trades in November 2025) lack measurable outcomes yet. The substantial dollar volume and multi-day execution warrant monitoring for any broader conviction shift.

QVT Financial LP sold 1,300,000 shares in 4 transactions for $26,304,500.00 at ROIV on 2025-11-19

QVT Financial LP executed 4 separate sales totaling 1,300,000 shares for $26,304,500.00 at blended average price $20.23 on 2025-11-19, reducing holdings by 6.7%. At same-ticker ROIV, prior sells show a 0 of 5 well-timed rate at the 90-day mark, with recent 2024 sales experiencing modest positive 90-day returns (+0.8%, +1.3%) and 2023 sales showing flat to negative outcomes. The company is unprofitable (net income $-113,519,000.00 for latest full year) with severe revenue decline (-76.7% year-over-year) and minimal quarterly revenue ($1,571,000.00), yet current price $20.22 remains near the 52-week high (only -5.2% below $21.32), suggesting the market has not repriced for deteriorating fundamentals. This sale occurs against a backdrop of strong recent momentum (+12.6% in 30 days, +69.6% in 90 days), complicating interpretation of whether the disposition reflects confidence or hesitation given the insider's historical lack of timing success at this ticker.

QVT Financial LP sold 926,000 shares of ROIV across 2 transactions for $10,942,820.00; post-transaction holds 22.18M shares.

QVT Financial LP completed two separate sales totaling 926,000 shares for $10,942,820.00, executed at $11.77 and $11.82 on consecutive days (2024-09-25 to 2024-09-26), reducing its stake from 23.11M to 22.18M shares (-4.0%). The transaction price of $11.82 (blended) sits 2.1% above the current price of $11.57 but remains 12.3% below the 52-week high of $13.19, suggesting the insider sold within a depressed zone of its recent range. Roivant's fundamentals show strong growth (revenue up 103.6% year-over-year) and a low P/E of 1.81, yet QVT's prior five trades at this same ticker all executed on 2023-09-28 with uniformly poor outcomes: each achieved a 0.00% well-timed rate at the 90-day mark (the stock rose after every sale). This filing adds to a pattern of historically poorly-timed exits at ROIV, though the current sale's proximity to the 52-week high provides marginal tactical context that prior comparable trades lacked.